전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-1 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

rAAV2-CBSB-hRPE65 (rAAV2-CBSB-hRPE65)

Amaurosis of Leber; Retinal Diseases · Amaurosis of Leber

#AmaurosisofLeber#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleAskBio IncPhase 1

d3990 (rAAV2.5-CMV-minidystrophin, rAAV2.5-CMV-minidystrophin (d3990))

Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy

#DuchenneMuscularDystrophy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleUniversity of AlbertaPhase 2

rAAV2.REP1 vector (rAAV2.REP1 vector)

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleNantes University HospitalPhase 2

rAAV2/4.hRPE65 (rAAV2/4.hRPE65)

Leber Congenital Amaurosis · Leber Congenital Amaurosis

#LeberCongenitalAmaurosis#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 1 (rAAV2/5-PBGD vector dosage 1)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 2 (rAAV2/5-PBGD vector dosage 2)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 3 (rAAV2/5-PBGD vector dosage 3)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 4 (rAAV2/5-PBGD vector dosage 4)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleUniQure Biopharma B.V.Phase 2

rAAV2/5-hNAGLU (rAAV2/5-hNAGLU)

Sanfilippo Syndrome B · Sanfilippo Syndrome B

#SanfilippoSyndromeB#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleBeacon TherapeuticsPhase 2

rAAV2tYF-CB-hRS1 (rAAV2tYF-CB-hRS1)

X-linked Retinoschisis · X-linked Retinoschisis

#X-linkedRetinoschisis#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleBeacon TherapeuticsPhase 3

rAAV2tYF-GRK1-hRPGRco (rAAV2tYF-GRK1-hRPGRco)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeacon TherapeuticsPhase 2

rAAV2tYF-PR1.7-hCNGB3 (rAAV2tYF-PR1.7-hCNGB3)

Achromatopsia · Achromatopsia

#Achromatopsia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleEunice Kennedy Shriver National…Phase 1

recombinant adenovirus containing the ornithine transcarbamylase gene (recombinant adenovirus containing the ornithine transcarbamylase gene)

Ornithine Transcarbamylase Deficiency Disease · Ornithine Transcarbamylase Deficiency Di

#OrnithineTranscarbamylaseDeficie#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 3

recombinant human thrombopoietin (rhTPO, recombinant human thrombopoietin, recombinant human thrombopoietin (rhTPO); rituximab)

Purpura; Idiopathic Thrombocytopenic Purpura · Purpura

#Purpura#Antibody#Phase3#monoclonal-antibody#IdiopathicThrombocytopenicPurpur+1
Trials 1Status Discontinued
AntibodyLimited DatastaleThe Affiliated Hospital of Qing…Phase 1

HS627 (recombinant monoclonal antibody against human epidermal growth factor receptor injection, recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#monoclonal-antibody#The
Trials 1Status Active
AntibodyLimited DatastaleDan LiangPhase 2

adalimumab (Humira, reduction or discontinuation of Adalimumab)

Uveitis; Adalimumab · Uveitis

#Uveitis#Antibody#Phase2#monoclonal-antibody#Adalimumab+1
Trials 1Status Active
AntibodyLimited DatastaleUniversity of UtahPhase 1

regorafenib + panitumumab (regorafenib + panitumumab)

KRAS and NRAS Wild-type Colorectal Cancer · KRAS and NRAS Wild-type Colorectal Cance

#KRASandNRASWild-typeColorectalCa#Antibody#Phase1#monoclonal-antibody#University
Trials 1Status Discontinued
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab+rHuPH20)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPreclinical

response to infliximab associated with methotrexate (response to infliximab associated with methotrexate)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#monoclonal-antibody#Janssen
Trials 1Status Active

101 / 103 pages

← PreviousNext →